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Abstract
Locoregional recurrence accounts for majority of the
treatment failures in oral cancer patients. Current study
aimed to determine the predictors of recurrence and
survival in patients with biopsy proven Squamous Cell
Carcinoma (SCC) of the oral cavity. This study included 88
patients of squamous cell carcinoma treated at our
institution from 2007 till 2013. Primary intervention was
surgery in all patients with radiation and chemotherapy in
selected patients. Primary end point was locoregional
recurrence, distant metastasis and death. Out of 88
patients, 23 (26.1%) patients developed locoregional
recurrence and 6 (6.8%) patients developed distant
metastasis. Overall survival rate was 77.3%. Follow up
ranged from 1 month to 63 months with mean of
17.8±16.2. On multivariate analysis, lymph node
involvement and loco-regional recurrence were
independent parameters related to decrease overall
survival. Lymphovascular invasion, perineural spread,
TNM stage and lymph node involvement had significant
impact on recurrence.
Keywords: Oral cavity, Squamous cell carcinoma,
Recurrence, Metastasis, Radiotherapy.
Introduction
Oral Squamous Cell Carcinoma (OSCC) is the 3rd most
common solid tumour in Pakistan, mainly due to
addiction. A significant number of recurrent cancers had
clear margins and negative neck nodes. This "negative"
histologic status and subsequent higher incidence of
locoregional recurrence have led many researchers to
evaluate the possible predictors of recurrence.1
The current study evaluates the impact of various
clinicopathological features on survival in Pakistani
population.
Case Series
This was a descriptive cross sectional study. Sample size
was calculated by using SAS Sample size calculator on the
basis of "Sample Sizes Based on the Log-Rank Statistic in
Complex Clinical Trials". A two-sided log rank test with an
overall sample size of 84 subjects was achieved with 80%
power at a 0.050 significance level to detect a hazard ratio
of 0.5 when the proportion surviving in the group is
0.748.2 A total of 88 patients with biopsy proven OSCC
were selected through non-probability purposive
sampling.
Patients who underwent surgical treatment for OSCC with
"intent to cure" at Patel Hospital from April 2006 till
August 2013 were retrospectively included in this study
after obtaining their informed consent. Patients who
received palliative treatment and patients who already
received initial treatment outside our institution were
excluded. The study was approved from institutional
ethics committee. Study end points were locoregional
recurrence (LR), distant metastasis (DM) and death.
Causes of death were classified into: (1) death from LR (2)
death from DM (3) death from non-tumour event (4) and
death from bronco-pulmonary pneumonia.
Pearson Chi-square test was applied to see the correlation
of clinicopathological features with overall recurrence
(OR) (LR and DM) and overall survival (OS). Univariate
survival curves were plotted using the Kaplan-Meier
method, and statistical differences were determined by
using the log-rank test. Multivariate analysis was
performed using the stepwise backward LR Cox
regression hazards model. A p value of <0.05 was
considered significant.
Results
A total of 88 patients were included in the study. Male to
female ratio was 2.3:1. Patients' age ranged from 22-72
years with mean±SD of 48.26±12. Seventy five (85.2%)
cases had history of addiction to different substances
including cigarette, pan, betel nut, ghutka (crushed
areca nut, tobacco & catechu), naswar (tobacco snuff),
etc. Buccal mucosa was the most common site, involving
46 (52%) cases. Tumour size ranged from 0.5 to 6.5 cm
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with mean±SD of 3.16±1.39.Tumour thickness ranged
from 2 to 60mm with a mean of 14.2±11.68 and median
of 11mm. Bone involvement was seen in 5 out of 7 cases
which had undergone mandibulectomy. DM was not
present in any case at the time of initial diagnosis.
Human Papilloma Virus (HPV) infection status could not
be checked in these cases since this test is not routinely
performed in commercial diagnostic laboratories of our
city.
Eleven (12.5%) cases were treated with surgical excision
alone, 73 (82.9%) cases received additional radiotherapy
and 4 (4.6%) cases had concurrent chemotherapy and
radiotherapy. All of the patients received radiation dose
of 6600 cGy. The chemotherapy protocol administered in
all four patients was 3 cycles of Cisplatin on 3 weekly
basis. Reconstruction was done in 52 (59%) cases. Biologic
and targeted therapy was not used in any case. Lymph
node dissection was performed in 78 cases.
Follow up duration ranged from 1 to 63 months with a
mean of 17.8±16.2 and median of 11 months. Twenty
three (26.1%) patients developed LR and 6 patients
developed DM. Three of these patients developed brain
metastasis, 2 developed lung metastasis and 1 developed
both brain and lung metastasis. Overall survival rate was
77.3%. Twelve (13.6%) cases died of LR, 6 (6.8%) cases
died of DM and single case each with bronchopulmonary
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Table-1: Correlation of clinicopathological features of oral squamous cells carcinoma
with locoregional recurrence.
Clinicopathological                                      Overall Recurrence                            p Value
features                                                          Yes                                   No
Gender                                                                                                                                             
Male                                                             12 (13.7%)                    49 (55.6%)                   0.059
Female                                                        11 (12.5%)                    16 (18.2%)                         
Tumour size                                                                                                                                  
<2cm                                                           04 (5.4%)                     14 (18.9%)                   0.927
2-4cm                                                          10 (13.5%)                    27 (36.5%)                         
>4cm                                                           05 (6.8%)                     14 (18.9%)                         
Tumour thickness                                                                                                                      
<4 mm                                                         05(6.8%)                        03(4.1%)                     0.035
>4mm                                                        17(23.3%)                     48(65.8%)                         
Tumour grade                                                                                                                              
Well differentiated                                  04 (4.8%)                     17 (20.2%)                   0.539
Moderately differentiated                    15 (17.9%)                      37 (44%)                          
Poorly differentiated                               04 (4.8%)                      07 (8.3%)                          
Lymphovascular invasion                                                                                                      
Present                                                         04 (5.6%)                      02 (2.8%)                    0.028
Absent                                                         16 (22.5%)                     49 (69%)                          
Perineural Invasion                                                                                                                  
Yes                                                                 06(7.4%)                        04(4.9%)                     0.018
No                                                                   17(21%)                       54(66.7%)                         
Surgical margins                                                                                                                        
Clear (>5 mm away)                               04 (4.5%)                     24 (27.3%)                   0.052
Close (<5mm away)                              18 (20.5%)                    32 (36.3%)                         
Involved by tumour                                 01 (1.1%)                     09 (10.2%)                         
Bone Involvement (n=7)                                                                                                       
Present                                                        02 (28.6%)                    03 (42.9%)                   0.714
Absent                                                         01 (14.3%)                    01 (14.3%)                         
Lymph node dissection                                                                                                           
Performed                                                  18 (20.5%)                    60 (68.1%)                   0.087
Not performed                                           05 (5.7%)                      05 (5.7%)                          
Tumour stage                                                                                                                              
Stage I                                                          04 (4.6%)                     11 (12.6%)                   0.029
Stage II                                                         04 (4.6%)                     18 (20.7%)                         
Stage III                                                        02 (2.3%)                     15 (17.2%)                         
Stage IVA                                                   13 (14.9%)                      20 (23%)                          
Table-2: Correlation of clinicopathological features of oral squamous cells carcinoma
with overall survival.
Clinicopathological                                         Overall Survival                               p Value
features                                                               Alive                         Expired
Tumour size                                                                                                                                  
<2cm                                                                14 (18.9%)                   04 (5.4%)                  0.86
2-4cm                                                                27 (36.5%)                 10 (13.5%)                     
>4cm                                                                15 (20.3%)                   04 (5.4%)                      
Tumour thickness                                                                                                                      
<4 mm                                                              05 (6.8%)                    03 (4.1%)                 0.372
>4mm                                                              50 (68.5%)                 15 (20.5%)                     
Tumour grade                                                                                                                              
Well and moderately differentiated         58 (69%)                   15 (17.9%)               0.071
Poorly differentiated                                     06 (7.1%)                      05 (6%)                        
Lymphovascular invasion                                                                                                      
Present                                                               04 (5.6%)                    02 (2.8%)                 0.381
Absent                                                               53 (74.6%)                 12 (16.9%)                     
Surgical margins                                                                                                                        
Clear (>5 mm away)                                    25 (28.4%)                   03 (3.4%)                 0.083
Close (<5mm away)                                    34 (38.6%)                 16 (18.2%)                     
Involved by tumour                                      09 (10.2%)                   01 (1.1%)                      
Lymph node involvement                                                                                                     
Present                                                              21 (23.9%)                 13 (14.8%)               0.006
Absent                                                               47 (53.4%)                    07 (8%)                        
Pathologic N stage                                                                                                                    
N0                                                                       47 (53.4%)                    07 (8%)                  0.014
N1                                                                       11 (12.5%)                   04 (4.5%)                      
N2a                                                                      02 (2.3%)                             -                               
N2b                                                                        07 (8%)                      08 (9.1%)                      
N2c                                                                       01 (1.1%)                    01 (1.1%)                      
N3                                                                                 -                                      -                               
Tumour stage                                                                                                                              
Stage I                                                               12 (13.8%)                   03 (3.4%)                 0.056
Stage II                                                                20 (23%)                    02 (2.3%)                      
Stage III                                                             15 (17.2%)                   02 (2.3%)                      
Stage IVA                                                            20 (23%)                   13 (14.9%)                     
Overall recurrence                                                                                                                     
Yes                                                                      10 (11.4%)                 13 (14.8%)             <0.001
No                                                                       58 (65.9%)                    07 (8%)                        
pneumonia and non-tumour related cause.
In univariate analysis, <4mm tumour thickness,
lymphovascular invasion (LVI), perineural invasion (PNI)
and TNM stage were significantly associated with
increased LR (Table-1). In multivariate analysis, LVI was the
only independent parameter related to LR (p = 0.004).
In univariate analysis, lymph node involvement, higher
nodal stage and OR were significantly associated with
decreased overall survival (Table-2). In multivariate
analysis, lymph node involvement and LR were the
independent parameters related to decreased OS (p=
0.004 and p= 0.001, respectively).
Discussion
OS of OSCC ranges from 54.6% -74.8% in reported
literature.2 OS in our series was 77.3% and recurrence free
survival was 73.9%.
OSCC is more commonly encountered in males with M:F
of 1.5:1.3 In our study, M:F was 2.3:1. Studies have
reported higher incidence in patients above 45 years.4 In
our experience, the LR rate and death rate were almost
similar in the two age groups.
High incidence of OSCC in the subcontinent is attributed
to the addiction of cigarette and tobacco.5 We evaluated
the risk of developing recurrence with the addiction but
no correlation was observed. The commonest site of
tumour involvement in the subcontinent population is
buccal mucosa due to tobacco chewing.5 Buccal mucosa,
tongue and lower alveolar ridge were the most common
tumour sites in our series. The highest rate of recurrence
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Figure-1: (A) Kaplan-Meier curve for overall survival. Kaplan-Meier curves showing significant reduction is overall survival with (B) Lymph node involvement (C) Nodal stage and (D)
Recurrence.
was seen in the tumours of lower alveolar ridge.
Several studies have demonstrated that tumour size is
related with lymph node involvement, recurrence and
overall survival.6 In our study, tumour recurrence rate
and death rate was similar in different categories of
tumour size. Tumour thickness is a better predictor of
disease progression.7 In contrast, we observed
significantly higher recurrence rate in patients with less
tumour thickness.
Histologic grade has proved to be a good predictor of
prognosis in few studies while other studies failed to
demonstrate it.8 Although, poorly differentiated
tumours in our study showed the highest rate of
recurrence and death but statistical significance was not
achieved.
LVI is a well-known risk factor for LR and DM.7 After
multivariate analysis, LVI proved to be the only
independent factor predictive of recurrence in this study
(p=0.004). 
PNI is also related to tumour recurrence.9 In our cohort of
patients, PNI was significantly associated with a higher
recurrence rate (p=0.018) but it was not an independent
prognostic factor after multivariate analysis.
Tumour recurrence was observed in 2 out of 5 (40%)
patients of our study who had bone involvement. All
these patients, received additional radiotherapy which
was successful in achieving good disease control. Surgical
resection with closed margins was associated with the
highest recurrence rate (p=0.052) and death rate
(p=0.083) in our study. Interestingly, resections with
positive margins did not show poor outcome and
probably the adjuvant radiotherapy was successful in
controlling the tumour spread.
Cervical lymph node involvement is one of the most
important poor prognostic factors6 Lymph node
involvement and higher 'N' stage were significantly
associated with poor survival (p=0.006 and p=0.014
respectively), but no significant association was seen with
tumour recurrence. The highest death rate was seen in
N2b stage category. After multivariate analysis, lymph
node involvement proved to be the sole independent
factor predicting poor survival (p=0.004).
Tumour stage has well-established relation with the
survival in OSCC.9 We did not observe significant
difference in outcome among T stage categories.
However, when N stage was also combined with T stage
and an overall tumour stage was assessed, a significantly
higher recurrence rate was observed with higher tumour
stage (p=0.029), the maximum being seen in stage IV.
Moreover, higher tumour stage was also associated with
poor survival (p=0.056), the worst observed again in
stage IV.
The combination of reconstructive surgery and
radiotherapy has resulted in improved overall survival.10
We did not observe any difference in recurrence and
survival related to the treatment modalities used. Majority
of the patients were treated with surgery along with
radiotherapy which provided good disease control.
Twenty (27.3%) out of these 73 patients developed LR and
17 (23.2%) died of the disease.
LR and DM have adverse impact on survival.2 Similarly, we
observed significantly worse survival in these patients
(p<0.001). Thirteen (56.5%) out of 23 patients with LR and
all 6 patients with DM died of the disease.
Patient survival was adversely affected in the 20 -30
months' time span following treatment completion.  After
36 months, survival pattern remained stable (Figure-1A).
When the parameters adversely related to the survival
were analyzed by using Log rank test, the mean survival
duration of patients with lymph node involvement was
significantly lower than the mean survival duration of
patients without lymph node involvement (32.7 versus
50.6 months). Median survival duration was 15 months
with confidence interval of 8.05-21.9 and significant p
value of 0.002 (Figure-1B).
The mean survival duration of patients with nodal stage
N2c was significantly lower than the mean survival
duration of patients with nodal stage N0 (9 versus 50.6
months). Median survival duration was 9 months with
confidence interval of 9.0-9.0 and highly significant p
value of <0.001(Figure-1C).
The mean survival duration of patients with recurrence
was significantly lower than the mean survival duration of
patients who were disease-free (26.3 versus 54.5 months).
Median survival duration was 11 months with confidence
interval of 9.53-12.5 and highly significant p value of
<0.001 (Figure-1D).
Since this study was retrospectively conducted in a single
tertiary care center, it has few limitations including small
sample size, variable follow up duration and treatments
given to the patients. Therefore, prospective multi-
institutional studies on larger cohorts are needed to
validate the findings of these studies.
Conclusion
LVI, PNI, TNM stage and nodal involvement were
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identified to correlate with the poor outcome. Higher
recurrence rate in tumours with a thickness of <4mm and
clear margins point out towards the success of adjuvant
radiotherapy in controlling locally advanced disease and
considering this treatment option in early tumours also.
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